Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7882223 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29724424 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8073541 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7351826 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7353711 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL383562 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19183215 | 1.00 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4139877 | 0.79 | IDO1 (0.44) | — | |
| SCHEMBL4139874 | 0.79 | IDO1 (0.44) | — | |
| SCHEMBL4139879 | 0.79 | IDO1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0816317-B1 | PROCESS FOR PRODUCING TRANS-2-BROMOINDAN-1-OL | ICHIKAWA GOSEI KAGAKU KK (JP) | 2003-08-20 | — | — | EP | claimed |
| EP-0658537-B1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI KAGAKU KK (JP) | 1999-03-31 | — | — | EP | claimed |
| US-5841000-A | CONTINUOUSLY HYDROLYZING 1,2-DIBROMOINDANE WITHOUT ISOLATING IT | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-11-24 | — | — | US | claimed |
| EP-0816317-A1 | PROCESS FOR PRODUCING TRANS-2-BROMOINDAN-1-OL | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-01-07 | — | — | EP | claimed |
| US-5648534-A | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1997-07-15 | — | — | US | claimed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| JP-8245455-A | — | — | None | — | — | JP | disclosed |
| JP-8291095-A | — | — | None | — | — | JP | disclosed |
| JP-9056395-A | — | — | None | — | — | JP | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| EP-3093287-A1 | AN IODINE CATALYSED PROCESS FOR PREPARING HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS | Fundació Institut Català D'investigació Quimica (ES) | 2016-11-16 | — | — | EP | disclosed |
| US-5112834-A | Antisecretory and antiulcer | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-05-12 | — | — | US | disclosed |
| EP-0370056-A1 | NEW DIAZOLS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1990-05-30 | — | — | EP | disclosed |
| WO-1989000570-A1 | NEW DIAZOLS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1989-01-26 | — | — | WO | disclosed |
| EP-0299470-A1 | Imidazo[1,2-a]pyridines | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0144235-A2 | N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-06-12 | — | — | EP | disclosed |
| US-4340732-A | Butenolide herbicides and process for their preparation | INTERNATIONAL DEVELOPMENT RESEARCH CENTRE OTTAWA ONTARIO CANADA K1G 3H9 A COORP OF CANADA (CA) | 1982-07-20 | — | — | US | disclosed |
| JP-H00956395-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | GRIN2D 27/4885GRIN3B 17/4885GRIN1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.